|
|
|
|
| LEADER |
01761nam a2200361 u 4500 |
| 001 |
EB001999949 |
| 003 |
EBX01000000000000001162850 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian drug expert committee recommendation (final): Certolizumab pegol (Cimzia -- UCB Canada Inc.)
|h Elektronische Ressource
|b indication : treatment of adult patients with moderate-to severe plaque psoriasis who are candidates for systemic therapy
|
| 246 |
3 |
1 |
|a Certolizumab pegol (Cimzia -- UCB Canada Inc.)
|
| 246 |
3 |
1 |
|a Drug reimbursement recommendation Certolizumab pegol (Cimzia)
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c November 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (10 pages)
|
| 653 |
|
|
|a Insurance, Health, Reimbursement
|
| 653 |
|
|
|a Adult
|
| 653 |
|
|
|a Certolizumab Pegol / therapeutic use
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Certolizumab Pegol / economics
|
| 653 |
|
|
|a Immunosuppressive Agents / therapeutic use
|
| 653 |
|
|
|a Psoriasis / drug therapy
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|a https://www.ncbi.nlm.nih.gov/books/NBK565093
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a The CADTH Canadian Drug Expert Committee (CDEC) recommends that certolizumab pegol (CZP) be reimbursed for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy if certain conditions are met
|